Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Executive Vice President & CFO | May 04, 2020 | May 05, 2020 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | CFO and CBO | April 07, 2025 | April 08, 2025 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Chief Financial Officer | January 31, 2022 | February 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ayala Pharmaceuticals, Inc.
Report date May 04, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2030-05-04 | Direct | 50,000 |
Reported balance
After 2020-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-04 · Grant · Acquired 50,000 · Balance 50,000 F1: This award relates to an incentive grant awarded by the Compensation Committee and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on May 4, 2021, one-third on May 4, 2022, and will be fully vested on May 4, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This award relates to an incentive grant awarded by the Compensation Committee and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on May 4, 2021, one-third on May 4, 2022, and will be fully vested on May 4, 2023.
Phathom Pharmaceuticals, Inc.
Report date April 07, 2025 · Filed April 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,868 |
Reported balance
After 2025-04-07 transaction · row 1
1 source rowRow 1 · 2025-04-07 · Sale · Disposed 3,678 · Balance 89,868 F1: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $4.55 to $4.57. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 1,911.27 |
Reported balance
Holding disclosure · report date 2025-04-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,911.27 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $4.55 to $4.57. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
UroGen Pharma Ltd.
Report date January 31, 2022 · Filed February 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 5,248 |
Ending reported balance
After 2022-01-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-01-31 · Exercise / conversion · Acquired 666 · Balance 5,579 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Row 2 · 2022-01-31 · Sale · Disposed 331 · Balance 5,248 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,334 |
Reported balance
After 2022-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-01-31 · Exercise / conversion · Disposed 666 · Balance 1,334 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3: The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,500 |
Reported balance
After 2022-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-01-31 · Grant · Acquired 7,500 · Balance 7,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F4: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.72 · Expires 2032-01-31 | Direct | 30,000 |
Reported balance
After 2022-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-01-31 · Grant · Acquired 30,000 · Balance 30,000 F5: 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3: The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.
F4: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.
F5: 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2025 Filed Apr 8, 2025 17:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 3,678 | $4.55 | $16,739.68 |
DisclosureSEC source: 0000950170-25-052156 · ownership.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,868 F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $4.55 to $4.57. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 17:15 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0000950170-25-031042 · ownership.xml · derivative · entry 3 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-02-26 F2 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 17:15 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 72,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-031042 · ownership.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,546 F1 · shares: Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:24 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 6,583 | $6.59 | $43,370.78 |
DisclosureSEC source: 0000950170-25-008357 · ownership.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,546 F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $6.5855 to $6.6519. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 1,973 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 16:20 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,291 | $8.00 | $10,328.00 |
DisclosureSEC source: 0000950170-24-139062 · ownership.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,156 F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 14:51 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 4,325 | $11.72 | $50,689.00 |
DisclosureSEC source: 0000950170-24-084182 · ownership.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,447 F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · balance_after: Includes 1,009 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2024. Read SEC document |
| May 31, 2024 Filed May 31, 2024 18:37 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stoock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-067548 · ownership.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,763 F1 · shares: Represents restricted stock units ("RSUs") granted on May 31, 2024. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of December 18, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 16:30 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stoock | 3,435 | $11.10 | $38,128.50 |
DisclosureSEC source: 0000950170-24-043385 · ownership.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,263 F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Read SEC document |
| January 19, 2024 Filed Jan 22, 2024 20:22 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 6,307 | $7.75 | $48,900.06 |
DisclosureSEC source: 0001209191-24-002021 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,698 F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · balance_after: Includes 1,944 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 20:22 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001209191-24-002021 · doc4.xml · derivative · entry 3 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2034-01-17 F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 16:40 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,127 | $7.24 | $15,402.67 |
DisclosureSEC source: 0001209191-23-056288 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,061 F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices between $7.24 and $7.2893. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 16:55 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 11,681 | $8.95 | $104,544.95 |
DisclosureSEC source: 0001209191-23-054355 · doc4.xml · nonDerivative · entry 3 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,188 F2 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of performance stock units. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 16:55 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 811 | $7.80 | $6,325.80 |
DisclosureSEC source: 0001209191-23-054355 · doc4.xml · nonDerivative · entry 2 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,869 F2 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of performance stock units. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 16:55 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054355 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,680 F1 · shares: Represents shares earned with respect to a performance stock unit award granted on January 19, 2023 that contained a performance-vesting requirement that was satisfied on November 1, 2023. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 17:00 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 25,000 | $1.00 | $25,000.00 |
DisclosureSEC source: 0001209191-23-042455 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,180 F1 · shares: Represents restricted stock units ("RSUs") granted on July 14, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of July 14, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes 1,674 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023. Read SEC document |
| July 14, 2023 Filed Jul 21, 2023 20:30 UTC Amendment | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043162 · doc4a.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,180 F1 · shares: Represents restricted stock units ("RSUs") granted on July 14, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of July 14, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · price: This amendment is being filed to correct the transaction price included in the Form 4 filed on behalf of the Reporting Person on July 17, 2023. F3 · balance_after: Includes 1,674 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 18:32 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,960 | $11.41 | $22,367.72 |
DisclosureSEC source: 0001209191-23-034605 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,506 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022. F2 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices 11.41 and 11.5653. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 22, 2023 Filed May 23, 2023 12:15 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,110 | $12.87 | $27,164.98 |
DisclosureSEC source: 0001209191-23-031647 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,466 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022. F2 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices 12.87 and 13.06. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 15:18 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 3,439 | $7.27 | $25,001.53 |
DisclosureSEC source: 0001209191-23-023749 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,576 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022. F2 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 19:03 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,032 | $8.53 | $17,334.79 |
DisclosureSEC source: 0001209191-23-016023 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,015 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022. F2 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.3385 to $8.5524. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 19:32 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001209191-23-004337 · doc4.xml · derivative · entry 3 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-01-18 F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 19:32 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004337 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,047 F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes 1,706 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 16:10 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,159 | $9.60 | $20,726.40 |
DisclosureSEC source: 0001209191-22-058627 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,341 F1 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.59 to $9.8716. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 16:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048473 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 F1 · shares: Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| May 19, 2022 Filed May 20, 2022 17:17 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031085 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 F1 · shares: Represents restricted stock units ("RSUs") granted on May 19, 2022. One third (1/3) of the total number of RSUs granted vest on November 19, 2022, May 19, 2023 and November 19, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| May 13, 2022 Filed May 16, 2022 20:43 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | PurchaseCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-029446 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.90. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 20:50 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0001209191-22-023561 · doc4.xml · derivative · entry 2 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-04-04 F2 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on April 5, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 20:50 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023561 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents restricted stock units ("RSUs") granted on April 5, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of April 5, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:34 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001209191-22-006385 · doc4.xml · derivative · entry 5 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2032-01-31 F5 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:34 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006385 · doc4.xml · derivative · entry 4 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Ordinary Shares · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F4 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025. F4 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:34 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006385 · doc4.xml · derivative · entry 3 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334 Underlying: Ordinary Shares · 1,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:34 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 331 | $7.58 | $2,508.98 |
DisclosureSEC source: 0001209191-22-006385 · doc4.xml · nonDerivative · entry 2 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,248 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:34 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-006385 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:15 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067439 · doc4.xml · derivative · entry 3 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of November 30, 2021, October 1, 2022 and October 1, 2023. F3 · derivative.expiration_date: 1/3 of the shares underlying the stock options will vest on each of November 30, 2021, October 1, 2022 and October 1, 2023. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:15 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 2,587 | $12.03 | $31,121.61 |
DisclosureSEC source: 0001209191-21-067439 · doc4.xml · nonDerivative · entry 2 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,913 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:15 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-067439 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| June 05, 2021 Filed Jun 8, 2021 18:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $17.98 | $0.00 |
DisclosureSEC source: 0001209191-21-038841 · doc4.xml · derivative · entry 1 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of June 1, 2022, June 1, 2023 and June 1, 2024. Read SEC document |
| May 17, 2021 Filed May 18, 2021 15:36 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | PurchaseCommon Stock | 2,500 | $15.85 | $39,625.00 |
DisclosureSEC source: 0001209191-21-033402 · doc4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 20:57 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006710 · doc4.xml · derivative · entry 2 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024. F3 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024. Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 20:57 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001209191-21-006710 · doc4.xml · derivative · entry 1 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2031-01-30 F1 · derivative.exercise_date: 1/3 of the shares underlying the stock option will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053641 · doc4.xml · derivative · entry 2 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of October 1, 2021, October 1, 2022 and October 1, 2023. F3 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of October 1, 2021, October 1, 2022 and October 1, 2023. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $19.66 | $0.00 |
DisclosureSEC source: 0001209191-20-053641 · doc4.xml · derivative · entry 1 Henderson Molly · CIK 0001363812 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of October 1, 2021, October 1, 2022 and October 1, 2023. Read SEC document |
| May 04, 2020 Filed May 5, 2020 16:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOptions · Derivative | 50,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001493152-20-007732 · ownership.xml · derivative · entry 1 Henderson Molly · CIK 0001363812 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-04 F1 · derivative.exercise_date: This award relates to an incentive grant awarded by the Compensation Committee and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on May 4, 2021, one-third on May 4, 2022, and will be fully vested on May 4, 2023. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 25,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001493152-19-016008 · ownership.xml · derivative · entry 1 Henderson Molly · CIK 0001363812 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-10-24 F1 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2019 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on October 24, 2020, one-third on October 24, 2021, and will be fully vested on October 24, 2022. Read SEC document |
| April 11, 2019 Filed Apr 11, 2019 12:11 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 2,500 | $3.68 | $9,199.75 |
DisclosureSEC source: 0001493152-19-005147 · ownership.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,833 F1 · shares: Represents a voluntary at market stock purchase by the reporting person on the open market. Read SEC document |
| April 09, 2019 Filed Apr 10, 2019 09:12 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 100 | $3.85 | $385.00 |
DisclosureSEC source: 0001493152-19-005083 · ownership.xml · nonDerivative · entry 2 Henderson Molly · CIK 0001363812 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · shares: Represents a voluntary at market stock purchase by the reporting person on the open market. Read SEC document |
| April 09, 2019 Filed Apr 10, 2019 09:12 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 2,900 | $3.86 | $11,193.71 |
DisclosureSEC source: 0001493152-19-005083 · ownership.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,900 F1 · shares: Represents a voluntary at market stock purchase by the reporting person on the open market. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 17:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 125,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001493152-18-015367 · form4.xml · derivative · entry 1 Henderson Molly · CIK 0001363812 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2018-11-05 F1 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2018 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 5, 2019, one-third on November 5, 2020, and will be fully vested on November 5, 2021. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 18:37 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 5,000 | $1.89 | $9,450.00 |
DisclosureSEC source: 0001493152-18-008632 · form4.xml · nonDerivative · entry 1 Henderson Molly · CIK 0001363812 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents a voluntary at market stock purchase by the reporting person on the open market. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 16:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantStock Option · Derivative | 250,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001493152-18-008407 · form4.xml · derivative · entry 1 Henderson Molly · CIK 0001363812 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: One-third of the award will vest on June 6, 2019, one-third will vest on June 6, 2020, and the award will be fully vested on June 6, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.